Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:411-413
Published online before print January 4, 2007, doi: 10.1161/01.STR.0000254500.27412.ac
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/2/411    most recent
01.STR.0000254500.27412.acv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, U.
Right arrow Articles by Markus, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, U.
Right arrow Articles by Markus, H. S.
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Acute Cerebral Infarction
Right arrow Cerebral Lacunes
Right arrowRelated Article

(Stroke. 2007;38:411.)
© 2007 American Heart Association, Inc.


Research Reports

Asymmetric Dimethylarginine in Cerebral Small Vessel Disease

Usman Khan, MRCP; Ahamad Hassan, MRCP; Patrick Vallance, FRCP Hugh S. Markus, FRCP

From Centre for Clinical Neuroscience, St George’s University of London, London, UK.

Correspondence to Professor Hugh Markus, Centre for Clinical Neuroscience, St George’s University of London, Cranmer Terrace, London SW17 ORE, UK. E-mail hmarkus{at}sgul.ac.uk


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background and Purpose— Endothelial dysfunction may play a causal role in cerebral small vessel disease (SVD). Asymmetric dimethylarginine (ADMA), a circulating endogenous inhibitor of nitric oxide, has been implicated in endothelial dysfunction, particularly in hyperhomocystinemia, a known risk factor for SVD. We determined if ADMA was elevated in SVD, correlated with disease severity, and interacted with homocysteine.

Methods— ADMA and homocysteine levels were determined in 47 consecutive symptomatic SVD patients and 38 controls. SVD was graded by leukoariosis severity and number of lacunar infarcts.

Results— Mean (and SD) ADMA was higher in SVD patients compared with controls (0.814 [0.145] versus 0.747 [0.184] µmol/L; P=0.014) after controlling for age, gender, vascular risk factors, and creatinine clearance. Additionally controlling for homocysteine had only a small effect on this relationship (P=0.055). Mean homocysteine was higher in SVD cases compared with controls (15.14 [5.59] versus 12.49 [4.15] µmol/L; P=0.035). Leukoariosis grade correlated positively with ADMA (P=0.026) and homocysteine (P=0.003). Lacunar grade correlated with homocysteine (P=0.017), but not ADMA.

Conclusions— ADMA is independently associated with SVD and correlates with leukoariosis severity.


Key Words: ADMA • endothelial dysfunction • homocysteine • lacunar • leukoaraiosis • stroke


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cerebral small vessel disease (SVD) causes both lacunar infarction and more diffuse subcortical ischemic change referred to as leukoariosis. The pathogenesis of the underlying arteriopathy is uncertain but studies have implicated both endothelial dysfunction and hyperhomocysteinaemia, particularly when lacunar infarction is accompanied by confluent leukoariosis.1,2

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase.3 Elevated levels have been reported in cardiovascular disease,4 and it may play a role in mediating endothelial dysfunction seen in hyperhomocystinemia.5 ADMA is synthesized through arginine methylation by protein arginine methyltransferase, type 1. Protein arginine methyltransferase type 2 generates symmetric dimethylarginine, which has no endothelial nitric oxide synthase inhibitory action. Furthermore, symmetric dimethylarginine is largely eliminated through renal excretion, whereas most ADMA is metabolized by dimethylarginine dimethylaminohydrolase.

We compared ADMA levels between SVD patients and controls to test 2 hypotheses. First, that SVD is associated with elevated ADMA levels that correlate with SVD severity. Second, that there is a significant interaction between ADMA and homocysteine.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Study Population
Forty-seven white patients with SVD, defined using modified TOAST criteria,6 were recruited from inpatient and outpatient facilities. All had brain imaging, imaging of the extracranial carotid arteries, and ECG. Echocardiography was performed in 20 (43%). Thirty-eight white community controls free of symptomatic cerebrovascular disease were recruited by sampling family doctor lists from the same geographic regions as the patients. Sampling was stratified to provide similar distributions of age, gender, hypertension, hypercholesterolemia, and smoking history to patients. Local research ethics committees approved the protocol. Written informed consent was obtained from all participants.

Hypertension was defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg or current treatment with antihypertensive drugs. Diabetes mellitus was defined as a previous diagnosis of type I or type II diabetes, or at least 2 random glucose readings of >11.1 mmol/L or fasting blood glucose readings of >7.0 mmol/L. Hypercholesterolemia was defined as a serum cholesterol >5.2 mmol/L, or current statin therapy. A positive smoking history was recorded in those who had ever smoked.

Assays
All assays were performed blinded to the case identity. In patients, all samples were collected at least 3 months after the most recent stroke to exclude transient elevation in biochemical markers. Plasma ADMA and symmetric dimethylarginine were analyzed by high-pressure liquid chromatography. Serum homocysteine was measured as described previously.2 Because ADMA is handled by the kidneys, creatinine clearance was determined in cases and controls.

Grading of SVD
MRI was available in 41 cases (87.2%) and CT only in 6 cases (12.8%). Leukoariosis on MRI or CT was graded using a modified Fazekas scale into absent (0), mild (1), early confluent (2), and confluent (3). This method has been previously validated, and a good correlation was found between grading on CT and MRI.1 Lacunar infarcts (5 to 15 mm) were scored as absent (0), 1 to 2 lesions (1), 3 to 5 lesions (2), and >5 lesions (3). Because only 2 patients had lacunar infarction grade 3, for analysis patients were grouped into 2 categories: lacunar infarct grades 0 to 1 and 2 to 3.

Statistical Analysis
All biochemical markers underwent logarithmic transformation to normalize distributions before analysis. Multivariate logistic regression was used to control for age, gender, vascular risk factors, and creatinine clearance. ADMA levels were split into tertiles to enable logistic regression analysis, and odds ratios (ORs) and 95% CIs were calculated. Linear regression analysis was used to assess associations between ADMA, homocysteine, and SVD severity scores.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Subject Characteristics (Table 1)


View this table:
[in this window]
[in a new window]

 
TABLE 1. Demographics of Cerebral SVD and Control Groups

Age, gender, or vascular risk factors were well-matched between patients and controls.

Biochemical Markers in SVD Patients and Controls (Table 2)


View this table:
[in this window]
[in a new window]

 
TABLE 2. ADMA, SDMA, and homocysteine in SVD Cases and Controls

ADMA and homocysteine were increased in SVD patients compared with controls on univariate analysis and multivariate analysis. In contrast, symmetric dimethylarginine levels did not differ. The OR for SVD increased with increasing tertile of ADMA. After controlling for age, OR (95% CI) for the middle compared with the lowest tertile was 3.94 (1.22 to 12.78; P=0.022), and for the upper compared with the lowest tertile 4.80 (1.36 to 16.96; P=0.015). After additionally controlling for gender, vascular risk factors, and creatinine clearance, the ORs were 6.40 (1.20 to 34.16; P=0.030) and 10.04 (1.70 to 59.27; P=0.011), respectively.

Associations Between ADMA and Homocystine
There was no correlation between ADMA and homocysteine (R=0.114, P=0.329). The positive association between AMDA and SVD on multivariate analysis (P=0.014) was only slightly attenuated after additionally controlling for homocysteine (P=0.055). Similarly, the association between homocysteine and SVD (P=0.035) was attenuated slightly after additionally controlling for ADMA (P=0.055).

Differences in ADMA and Homocysteine Between Cerebral SVD Subtypes (Figure)


Figure 1
View larger version (19K):
[in this window]
[in a new window]

 
Correlation between ADMA and homocysteine levels (µmol/L) and leukoariosis and lacunar grade. Error bars indicate 95% CI.

Leukoariosis grade correlated positively with both ADMA (R=0.324, P=0.026) and homocysteine (R=0.433, P=0.003). There was no correlation between the lacunar grade and ADMA (R=0.029, P=0.849), but a positive correlation with homocysteine (R=0.362, P=0.017).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
We found ADMA was elevated in SVD after controlling for vascular risk factors and correlated with leukoariosis severity but not lacunar grade. Homocysteine was also elevated in SVD, and in contrast was correlated with both leukoariosis severity and lacunar grade. These findings may be consistent with ADMA mediating smaller perforator damage, contributing to leukoariosis, and homocysteine acting on both smaller and larger perforators additionally contributing to lacunes. A role for ADMA in mediating endothelial dysfunction in hyperhomocystinemia has been proposed,5 but we failed to demonstrate significant interaction between these two biomarkers.

The association of ADMA with atherosclerosis7 may offer an alternative explanation for the elevation of ADMA seen in SVD. Undetected atherosclerosis elsewhere in the vascular tree could result in high ADMA levels. However, several factors argue against this. SVD patients and controls were well-matched for vascular risk factors. Thirty-nine of 47 SVD patients had no evidence of plaque on extracranial vessel imaging. Eight patients had minor plaque (≤30% stenosis). None of the patients who had echocardiography had evidence of a cardiac or aortic atherosclerosis. Of the 47 SVD patients, only 1 had a history of myocardial infarction and 2 had symptomatic peripheral vascular disease.

Our findings demonstrate an association between SVD and ADMA and are consistent with, but do not prove, a role in disease pathogenesis. Our findings need to be replicated in a larger sample and in a prospective study to examine causality.


*    Acknowledgments
 
Sources of Funding

This work is supported by a Stroke Association grant (Prog 3).

Disclosures

None.

Received August 17, 2006; accepted September 13, 2006.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Hassan A, Hunt BJ, O’Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoariosis. Brain. 2003; 126: 424–432.[Abstract/Free Full Text]
  2. Hassan A, Hunt BJ, O’Sullivan M, Bell R, D’Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004; 127: 212–219.[Abstract/Free Full Text]
  3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339: 572–575.[CrossRef][Medline] [Order article via Infotrieve]
  4. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens. 2006; 24: 611–619.[Medline] [Order article via Infotrieve]
  5. Lentz SR, Rodionov RN, Dayal S. Hyperhomocystinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl. 2003; 4: 61–65.[Medline] [Order article via Infotrieve]
  6. Adams HP, Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35–41.[Abstract/Free Full Text]
  7. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study. Atherosclerosis. 2006; Epub.

Related Article:

The Thr715Pro Polymorphism of the P-Selectin Gene Is Not Associated With Ischemic Stroke Risk
Julia Ferrari, Sandra Rieger, Georg Endler, Stefan Greisenegger, Marion Funk, Thomas Scholze, Wilfried Lang, Wolfgang Lalouschek, and Christine Mannhalter
Stroke 2007 38: 395-397. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
StrokeHome page
P. B. Gorelick and J. V. Bowler
Advances in Vascular Cognitive Impairment 2007
Stroke, February 1, 2008; 39(2): 279 - 282.
[Full Text] [PDF]


Home page
StrokeHome page
H. Dayoub, R. N. Rodionov, C. Lynch, J. P. Cooke, E. Arning, T. Bottiglieri, S. R. Lentz, and F. M. Faraci
Overexpression of Dimethylarginine Dimethylaminohydrolase Inhibits Asymmetric Dimethylarginine-Induced Endothelial Dysfunction in the Cerebral Circulation
Stroke, January 1, 2008; 39(1): 180 - 184.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
H. S. Markus
Genes, endothelial function and cerebral small vessel disease in man
Exp Physiol, January 1, 2008; 93(1): 121 - 127.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Tsuda
Asymmetric Dimethylarginine and Hypertension in Cerebral Small Vessel Disease
Stroke, July 1, 2007; 38(7): e48 - e48.
[Full Text] [PDF]


Home page
StrokeHome page
U. Khan and H. S. Markus
Response to Letter by Tsuda
Stroke, July 1, 2007; 38(7): e49 - e49.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/2/411    most recent
01.STR.0000254500.27412.acv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, U.
Right arrow Articles by Markus, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, U.
Right arrow Articles by Markus, H. S.
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Acute Cerebral Infarction
Right arrow Cerebral Lacunes
Right arrowRelated Article